UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/β-catenin signaling pathway

BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy worldwide. Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), is becoming widely used in ovarian cancer treatment. The overall survival of ovarian cancer has not been significantly changed over the past decades and ovar...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenjing, Li, Min, Chen, Youguo, Gu, Xinxian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447717/
https://www.ncbi.nlm.nih.gov/pubmed/34535173
http://dx.doi.org/10.1186/s13048-021-00877-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447717/
https://www.ncbi.nlm.nih.gov/pubmed/34535173
http://dx.doi.org/10.1186/s13048-021-00877-y

Ejemplares similares